1
|
Chauchet X, Calloud S, LLoveras P, Bosson N, Legrand M, Chatel L, Cons L, Lesnier A, Malinge P, Pontini G, Guillamo C, Shchelokov D, Demin O, Ravn U, Moine V, Daubeuf B, Magistrelli G, Poitevin Y, Salgado-Pires S, Shang L, Fischer N, Ferlin W, Masternak K. Abstract 2951: NI-2901, an affinity-optimized CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade. Cancer Res 2023. [DOI: 10.1158/1538-7445.am2023-2951] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2023]
Abstract
Abstract
To enhance efficacy of anti-PD-1/PD-L1 antibodies, many combinations with various therapeutic agents are being investigated. Blocking the CD47/SIRPα myeloid checkpoint with monoclonal antibodies (mAbs) or decoy receptors is emerging as an effective approach to mobilize dendritic cells and macrophages to support T-cell mediated antitumor responses. The benefit of combining CD47/SIRPα and PD-1/PD-L1 blockade to improve tumor control has been convincingly demonstrated in preclinical models and is now being explored in patients. However, CD47 mAbs are hindered by ubiquitous CD47 expression, leading to pharmacokinetic (PK) and safety issues.NI-2901, an IgG4 CD47xPD-L1 bispecific antibody (bsAb), was generated using the κλ-body platform. In vitro assays were used to characterize its binding profile and checkpoint inhibition as well as its capacity to enhance T-cell activation and macrophage-mediated phagocytosis of tumor cells. PD-L1-independent CD47 antitumor activity was assessed in vivo in a PD-L1-negative xenograft model and compared to the anti-CD47 magrolimab analog. PK and tolerability of NI-2901 were evaluated in non-human primates (NHP), allowing for translational modeling to predict PK and dosing regimens in humans. Consistent with its intermediate affinity to CD47, NI-2901 shows lower binding to RBC as compared to magrolimab analog and is still able to induce CD47/SIRPα blockade on PD-L1-negative tumor cells, that is significantly enhanced once PD-L1 is expressed. As a result, the bsAb is able to enhance the phagocytosis of PD-L1-negative and -positive tumor cell lines induced by mAbs targeting tumor-associated antigens (e.g. rituximab, trastuzumab and anti-CD19) and demonstrates in vivo activity in the Raji B-cell lymphoma xenograft model. Given its high affinity for PD-L1, NI-2901 triggers an effective blockade of the PD-1/PD-L1 interaction, inducing T-cell activation in vitro to a degree similar to anti-PD-L1 benchmark antibodies atezolizumab and avelumab. In immunocompetent huCD47/huSIRPα-transgenic mice engrafted with MC38 cells engineered to express human PD-L1 and CD47, NI-2901 displayed significant anti-tumor activity. In a NHP study, NI-2901 was well-tolerated after four weekly injections at 30mg/kg, showing no signs of hemotoxicity. In contrast, the magrolimab analog induced a significant drop in RBC already after a single injection at 10mg/kg. PK modeling and simulations in humans suggest a more favorable dosing regimen as compared to CD47 targeted approaches. In conclusion, NI-2901, a dual immune checkpoint inhibitor, triggered effective T-cell activation and enhanced phagocytosis of tumor cells. Also, NI-2901 demonstrated significant antitumor activity in vivo and is therefore expected to show improved clinical efficacy over PD-1/PD-L1 blockade alone. The bsAb was well-tolerated in NHP without inducing RBC or platelet depletion.
Citation Format: Xavier Chauchet, Sebastien Calloud, Pauline LLoveras, Nicolas Bosson, Margaux Legrand, Laurence Chatel, Laura Cons, Adeline Lesnier, Pauline Malinge, Guillemette Pontini, Christophe Guillamo, Dmitry Shchelokov, Oleg Demin, Ulla Ravn, Valéry Moine, Bruno Daubeuf, Giovanni Magistrelli, Yves Poitevin, Susana Salgado-Pires, Limin Shang, Nicolas Fischer, Walter Ferlin, Krzysztof Masternak. NI-2901, an affinity-optimized CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2951.
Collapse
Affiliation(s)
- Xavier Chauchet
- 1Light Chain Bioscience – Novimmune SA, Plan-les-Ouates, Switzerland
| | - Sebastien Calloud
- 1Light Chain Bioscience – Novimmune SA, Plan-les-Ouates, Switzerland
| | - Pauline LLoveras
- 1Light Chain Bioscience – Novimmune SA, Plan-les-Ouates, Switzerland
| | - Nicolas Bosson
- 1Light Chain Bioscience – Novimmune SA, Plan-les-Ouates, Switzerland
| | - Margaux Legrand
- 1Light Chain Bioscience – Novimmune SA, Plan-les-Ouates, Switzerland
| | - Laurence Chatel
- 1Light Chain Bioscience – Novimmune SA, Plan-les-Ouates, Switzerland
| | - Laura Cons
- 1Light Chain Bioscience – Novimmune SA, Plan-les-Ouates, Switzerland
| | - Adeline Lesnier
- 1Light Chain Bioscience – Novimmune SA, Plan-les-Ouates, Switzerland
| | - Pauline Malinge
- 1Light Chain Bioscience – Novimmune SA, Plan-les-Ouates, Switzerland
| | | | | | | | - Oleg Demin
- 2InSysBio UK Limited, Edinburgh, United Kingdom
| | - Ulla Ravn
- 1Light Chain Bioscience – Novimmune SA, Plan-les-Ouates, Switzerland
| | - Valéry Moine
- 1Light Chain Bioscience – Novimmune SA, Plan-les-Ouates, Switzerland
| | - Bruno Daubeuf
- 1Light Chain Bioscience – Novimmune SA, Plan-les-Ouates, Switzerland
| | | | - Yves Poitevin
- 1Light Chain Bioscience – Novimmune SA, Plan-les-Ouates, Switzerland
| | | | - Limin Shang
- 1Light Chain Bioscience – Novimmune SA, Plan-les-Ouates, Switzerland
| | - Nicolas Fischer
- 1Light Chain Bioscience – Novimmune SA, Plan-les-Ouates, Switzerland
| | - Walter Ferlin
- 1Light Chain Bioscience – Novimmune SA, Plan-les-Ouates, Switzerland
| | | |
Collapse
|
2
|
Chauchet X, Calloud S, Legrand M, Cons L, Chatel L, Lloveras P, Burnet-Merlin C, Hellequin L, Bosson N, Malinge P, Pleche N, Bourguignon J, Pontini G, Guillamo C, Ravn U, Moine V, Daubeuf B, Poitevin Y, Magistrelli G, Shang L, Ferlin W, Masternak K. Abstract 3428: NI-2901, a CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade with fine-tuned affinity to reduce erythrocyte binding and improve biodistribution. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-3428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Blocking the CD47/SIRPα checkpoint has recently emerged as an effective approach to mobilize the myeloid cell compartment and to improve antitumor responses in the clinic. Preclinical models have demonstrated the synergistic benefit of combined CD47/SIRPα and PD-1/PD-L1 blockade. Combinations of monoclonal antibodies (mAbs) targeting these two checkpoint pathways are being explored in the clinic. CD47xPD-L1 bispecific antibodies (bsAbs) stand as an attractive alternative to mAb combinations, even more so as they provide a potential solution to improve the pharmacokinetic profile and safety issues faced by CD47 targeted-mAbs and SIRPα-Fc fusion proteins. CD47xPD-L1 bsAbs are expected to preferentially inhibit CD47 on PD-L1 expressing cells, displaying improved safety and pharmacokinetics, but also superior tumor microenvironment targeting capabilities. With the objective of finding the optimal CD47xPD-L1 bsAb, an array of bispecific antibodies (bsAbs) was generated associating a high affinity PD-L1 arm to CD47 arms with varying affinities. The CD47xPD-L1 bsAbs of human IgG4 isotype were generated using our fully human κλ body antibody platform. The candidate molecules were screened for binding and receptor-blocking activity and tested for their capacity to enhance T-cell activation and phagocytosis of tumor cells in the presence of anti-HER-2 mAb, trastuzumab. Selected bsAbs were also evaluated in a xenograft mouse model. The CD47xPD-L1 bsAbs demonstrated an effective blockade of the PD-1/PD-L1 interaction, being able to induce T-cell activation in vitro similar to the anti-PD-L1 clinical benchmark, atezolizumab. Consistent with their CD47 affinities, the bsAbs showed varying levels of CD47 blockade on PD-L1-negative cells and a low binding capacity to red blood cells. Nonetheless, trastuzumab-mediated phagocytosis of tumor cells expressing low levels of PD-L1 could be significantly enhanced by these bsAbs, confirming the PD-L1-independent activity of the CD47 blocking arms. The latter findings were corroborated in vivo using PD-L1-negative Raji cells in a xenograft mouse model. Selected bsAbs will be now tested for tolerability and pharmacokinetic profiles in human-CD47/human-SIRPα transgenic mice. Lead candidate(s) will be evaluated further for PK and safety attributes in non-human primates in early Q1, 2022.
Citation Format: Xavier Chauchet, Sébastien Calloud, Margaux Legrand, Laura Cons, Laurence Chatel, Pauline Lloveras, Coline Burnet-Merlin, Louis Hellequin, Nicolas Bosson, Pauline Malinge, Nicolas Pleche, Jérémie Bourguignon, Guillemette Pontini, Christophe Guillamo, Ulla Ravn, Valéry Moine, Bruno Daubeuf, Yves Poitevin, Giovanni Magistrelli, Limin Shang, Walter Ferlin, Krzysztof Masternak. NI-2901, a CD47xPD-L1 bispecific antibody for dual immune checkpoint blockade with fine-tuned affinity to reduce erythrocyte binding and improve biodistribution [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3428.
Collapse
Affiliation(s)
| | | | | | - Laura Cons
- 1Light Chain Bioscience - Novimmune SA, Geneva, Switzerland
| | | | | | | | | | - Nicolas Bosson
- 1Light Chain Bioscience - Novimmune SA, Geneva, Switzerland
| | | | - Nicolas Pleche
- 1Light Chain Bioscience - Novimmune SA, Geneva, Switzerland
| | | | | | | | - Ulla Ravn
- 1Light Chain Bioscience - Novimmune SA, Geneva, Switzerland
| | - Valéry Moine
- 1Light Chain Bioscience - Novimmune SA, Geneva, Switzerland
| | - Bruno Daubeuf
- 1Light Chain Bioscience - Novimmune SA, Geneva, Switzerland
| | - Yves Poitevin
- 1Light Chain Bioscience - Novimmune SA, Geneva, Switzerland
| | | | - Limin Shang
- 1Light Chain Bioscience - Novimmune SA, Geneva, Switzerland
| | - Walter Ferlin
- 1Light Chain Bioscience - Novimmune SA, Geneva, Switzerland
| | | |
Collapse
|